A compendium of mutational cancer driver genes
A fundamental goal in cancer research is to understand the mechanisms of cell
transformation. This is key to develo** more efficient cancer detection methods and …
transformation. This is key to develo** more efficient cancer detection methods and …
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Z Sondka, S Bamford, CG Cole, SA Ward… - Nature Reviews …, 2018 - nature.com
Abstract The Catalogue of Somatic Mutations in Cancer (COSMIC) Cancer Gene Census
(CGC) is an expert-curated description of the genes driving human cancer that is used as a …
(CGC) is an expert-curated description of the genes driving human cancer that is used as a …
HER2-targeted therapies—a role beyond breast cancer
DY Oh, YJ Bang - Nature reviews Clinical oncology, 2020 - nature.com
HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
[HTML][HTML] Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors
V Leko, SA Rosenberg - Cancer Cell, 2020 - cell.com
Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
K Kataoka, Y Shiraishi, Y Takeda, S Sakata… - Nature, 2016 - nature.com
Successful treatment of many patients with advanced cancer using antibodies against
programmed cell death 1 (PD-1; also known as PDCD1) and its ligand (PD-L1; also known …
programmed cell death 1 (PD-1; also known as PDCD1) and its ligand (PD-L1; also known …
High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor …
R Benayed, M Offin, K Mullaney, P Sukhadia… - Clinical Cancer …, 2019 - AACR
Purpose: Targeted next-generation sequencing of DNA has become more widely used in
the management of patients with lung adenocarcinoma; however, no clear mitogenic driver …
the management of patients with lung adenocarcinoma; however, no clear mitogenic driver …
[HTML][HTML] Genomic basis for RNA alterations in cancer
PCAWG Transcriptome Core Group Calabrese Claudia … - Nature, 2020 - nature.com
Transcript alterations often result from somatic changes in cancer genomes. Various forms of
RNA alterations have been described in cancer, including overexpression, altered splicing …
RNA alterations have been described in cancer, including overexpression, altered splicing …
[HTML][HTML] NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins
referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the …
referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the …